Abstract
Alzheimer’s disease (AD) represents a major public health challenge. It is the most common cause of dementia, the worldwide prevalence of which will double every 20 years in the foreseeable future. It would be good if it were possible to treat AD early to diminish its impact, but current evidence does not support early intervention. Vitamin E was no more effective than placebo in a study of vitamin E and donepezil against placebo in mild cognitive impairment (MCI). Vitamin E is associated with a higher rate of haemorrhagic events than is placebo. Neither donepezil nor galantamine has been shown to be helpful in retarding progression from MCI to AD. Gingko biloba was ineffective in delaying the onset of AD in a large prospective trial involving over 6,000 participants. Gamma secretase inhibitors have not yet been shown to retard the progression of AD and they seem to have a high incidence of adverse effects, especially rashes. Antibody therapy has not yet been shown to be helpful in the treatment of established AD, let alone its prevention. Metalloproteinase modifiers such as PBT2 may be useful AD therapies, but current evidence gives no support to their immediate use in pre-symptomatic AD. No evidence can yet be adduced to support the use of antibody therapies in MCI or early AD. Thus, it is clear that the early treatment of AD cannot be justified as yet, no matter how desirable this goal may be. Treatment of established AD with cholinesterase inhibitors and memantine, coupled with referral of interested patients to evaluative drug trials, is the best we can do at present.
Similar content being viewed by others
References
Alzheimer’s Disease International (2009) World Alzheimer report. Alzheimer’s Disease International, London
Barber R, O’Brien JT (2010) Structural brain imaging. In: Ames D, Burns A, O’Brien JT (eds) Dementia, 4th edn. Hodder Arnold, London, pp 97–108
Cummings JL, Benson DF (1992) Dementia: definition, prevalence, classification and approach to diagnosis. In: Cummings JL, Benson DF (eds) Dementia: a clinical approach. Butterworth-Heineman, Boston
DeKosky ST, Williamson JD, Fitzpatrick AL et al (2008) Ginkgo biloba for prevention of dementia: a randomized controlled trial. JAMA 300:2253–2262
Ellis K, Bush A, Darby D et al (2009) The Australian Imaging, Biomarkers and Lifestyle (AIBL) flagship study of ageing: methodology and characteristics of 1112 individuals recruited for a longitudinal study of Alzheimer’s disease. Int Psychogeriatr 21:672–687
Ferri CP, Prince M, Brayne C et al (2005) Global prevalence of dementia: a Delphi consensus study. Lancet 366:2112–2117
Ferri CP, Jackson J, Prince M (2010) The global challenge of dementia: what can be done. In: Ames D, Burns A, O’Brien JT (eds) Dementia, 4th edn. Hodder Arnold, London, pp 341–348
Frank B, Gupta S (2005) A review of antioxidants and Alzheimer’s disease. Ann Clin Psychiatry 17:269–286
Kurz A, Lautenschlager N (2010) Established treatments for Alzheimer’s disease: cholinesterase inhibitors and memantine. In: Ames D, Burns A, O’Brien JT (eds) Dementia, 4th edn. Hodder Arnold, London, pp 471–483
Lannfelt L, Blennow K, Zetterberg H et al (2008) Safety, efficacy and biomarker findings of PBT2 in targeting Aβ as a modifying therapy for Alzheimer’s disease: a phase IIa double blind randomised placebo controlled trial. Lancet Neurol 7:779–786
Lautenschlager N, Kurz A (2010) Managing the patient with mild cognitive impairment. In: Ames D, Burns A, O’Brien JT (eds) Dementia, 4th edn. Hodder Arnold, London, pp 379–387
Masters C (2010) The neuropathology of Alzheimer’s disease. In: Ames D, Burns A, O’Brien JT (eds) Dementia, 4th edn. Hodder Arnold, London, pp 417–431
McKhann G, Drachman D, Folstein M et al (1984) Clinical diagnosis of Alzheimer’s disease. Neurology 34:939–944
Pantel J, Hampel H (2010) Blood and CSF markers for Alzheimer’s disease. In: Ames D, Burns A, O’Brien JT (eds) Dementia, 4th edn. Hodder Arnold, London, pp 459–470
Petersen RC, Smith GE, Waring SC et al (1999) Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 56:303–308
Petersen RC, Doody R, Kurz A et al (2001) Current concepts in mild cognitive impairment. Arch Neurol 58:1985–1992
Ritchie C, McLean C, Beyreuther K, Masters C (2010) The central role of Aβ amyloid in the pathogenesis of Alzheimer’s disease. In: Ames D, Burns A, O’Brien JT (eds) Dementia, 4th edn. Hodder Arnold, London, pp 438–451
Villemagne VL, Rowe C (2010) Molecular brain imaging in dementia. In: Ames D, Burns A, O’Brien JT (eds) Dementia, 4th edn. Hodder Arnold, London, pp 120–127
Woodward M (2010) Drug treatments in development for Alzheimer’s disease. In: Ames D, Burns A, O’Brien JT (eds) Dementia, 4th edn. Hodder Arnold, London, pp 484–497
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ames, D. Negative argument for debate with V. O. Emery for J Neural Transmission. J Neural Transm 118, 1379–1381 (2011). https://doi.org/10.1007/s00702-011-0678-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00702-011-0678-6